We validated our findings in the CGGA325 and CGGA693 databases that ZNF503-AS2 showed a correlation with clinical characteristics and an association with MES molecular subtypes (S2 Fig), and the ROC curves indicated a good predictive ability for GBM, IDH mutations, 1p/19q codeletion, and molecular subtypes with poor prognosis (S3 Fig). This evidence concerns the gene ZNF503 and glioblastoma.